Home » Stocks » Innate Pharma

Innate Pharma S.A. (IPHA)

Stock Price: $3.90 USD -0.01 (-0.26%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 307.95M
Revenue (ttm) 96.42M
Net Income (ttm) -20.76M
Shares Out 78.96M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $3.90
Previous Close $3.91
Change ($) -0.01
Change (%) -0.26%
Day's Open 3.90
Day's Range 3.88 - 3.96
Day's Volume 3,872
52-Week Range 3.30 - 8.24

More Stats

Market Cap 307.95M
Enterprise Value 83.07M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 78.96M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.35
FCF / Share 0.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 12.28%
Payout Ratio n/a
Shares Short 22,653
Short Ratio 1.67
Short % of Float n/a
Beta -0.11
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 8.14
PS Ratio 3.19
PB Ratio 1.35
Revenue 96.42M
Operating Income -30.40M
Net Income -20.76M
Free Cash Flow 37.81M
Net Cash 224.88M
Net Cash / Share 2.84
Gross Margin 100.00%
Operating Margin -31.52%
Profit Margin -24.20%
FCF Margin 39.22%
ROA -8.18%
ROE -22.79%
ROIC -153.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(165.38% upside)
Current: $3.90
Target: 10.35
*Average 12-month USD price target from 6 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth-8.66%113.37%-
Gross Profit85.8193.9544.03
Operating Income-27.055.15-39.98
Net Income-20.763.05-48.39
Shares Outstanding74.7158.7854.35
Earnings Per Share-0.310.05-0.89
Operating Cash Flow34.92-32.53-48.06
Capital Expenditures-1.27-0.85-2.91
Free Cash Flow33.65-33.38-50.97
Cash & Equivalents219168116
Total Debt18.724.525.86
Net Cash / Debt200163110
Book Value21716785.96
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Innate Pharma S.A.
Country France
Employees 247
CEO Mondher Mahjoubi

Stock Information

Ticker Symbol IPHA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IPHA
IPO Date October 17, 2019


Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.